Short Interest in Innovent Biologics, Inc. (OTCMKTS:IVBXF) Increases By 8,549.4%

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 1,073,474 shares, a growth of 8,549.4% from the May 31st total of 12,411 shares. Based on an average daily volume of 24,954 shares, the days-to-cover ratio is presently 43.0 days.

Innovent Biologics Stock Up 5.0%

Shares of OTCMKTS IVBXF opened at $9.98 on Friday. The stock has a fifty day moving average price of $10.32 and a 200 day moving average price of $10.59. Innovent Biologics has a 1-year low of $9.10 and a 1-year high of $15.12.

About Innovent Biologics

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).